A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets

Epilepsy Clinical Trial

— Epilepsy  

Official title:

An Open Label, Randomized, Four-period, Two-sequence, Fully Replicated, Single-dose, Crossover Study of the Relative Bioavailability of Two Formulations of Extended-release Divalproex Sodium Tablets in Fed Patients With Stable Epilepsy.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01898676
• Other study ID #: RIHSC #13-019D
• Status: Recruiting
• Phase: Phase 1
• First received: June 17, 2013
• Last updated: July 9, 2013
• Start date: July 2013
• Est. completion date: December 2013

Study information

• Verified date: June 2013
• Source: Vince & Associates Clinical Research, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A study in stable epilepsy patients comparing levels of valproic acid after administration of brand and generic divalproex sodium extended release tablets.

Description:

Study consists of a screening visit, four treatment periods and a final follow-up visit. Each treatment period consists of a four night in-house stay followed by two outpatient visits. Each treatment period will be separated by a washout period. During each treatment period, safety evaluations will include vital signs, physical exams, safety laboratory tests, weight measurement, electrocardiograms, adverse event collection and concomitant medication recording. Pharmacokinetic blood samples will be collected during each treatment period. Seizure activity will be recorded in a seizure diary during the study. A standardized high-fat, high-calorie meal will be served prior to each dose during each treatment period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: December 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Able to understand, sign and date the informed consent form

• Male or female 18 to 55 years old with a diagnosis of epilepsy who are stable

• Body mass 18 to 34 kg/m, inclusive

• Is continuously receiving a fixed dose of their AED medication(s)for a minimum of 30 days prior to screening

• Stay on the same dosages of their routine concomitant medications throughout the study

• Healthy, as determined by pre-study medical history, vital signs, physical exam, ECG and the opinion of the investigator

• Normal renal function per laboratory test

• No clinically relevant labs.

• Negative for hepatitis B, C and HIV

• For females, negative pregnancy test

• Negative for drugs of abuse and alcohol

• Nonsmoker or has not smoked within the past six months.

• Some over-the-counter medications may be permitted at the discretion of the investigator

• Able to communicate well and comply with study procedures, requirements and restrictions

Exclusion Criteria:

• History or presence of clinically significant medical disorders

• Have a current psychiatric disorder

• History of status epilepticus within 90 days of screening

• Any other condition that the investigator would feel could interfere with the safety of the subject or the study protocol.

• Taking three or more AED medications

• Use of felbamate, aspirin, carbapenem antibiotics, rifampin, ritonavir, macrolide antibiotics, cholestyramine, and/or risperidone.

• Use of any investigational agent or medical device within 30 days of screening.

• History of clinically significant drug allergy that in the opinion of the investigator may compromise the subject's safety or study results.

• History of known hypersensitivity to divalproex sodium or its excipients

• History of alcohol or drug abuse or dependence in the past 5 years

• Consumed alcohol, caffeine or other xanthine-containing foods or beverages within 48 hours prior to each clinic admission.

• Consumed grapefruit and/or grapefruit containing products within days prior to admission to the clinic on Day -1 and they agree not to consume grapefruit and/or grapefruit containing products for the duration of their study involvement

• Participated in any strenuous physical exercise within 72 hours before admission to the clinic on Day 1 and agrees to abstain from the duration of their study involvement.

• Acute illness at screening and/or at admission to the clinic

• Lactose intolerance or unusual dietary habits.

• Blood donation within 8 weeks of admission to this study

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Epilepsy

Intervention

Drug:
• Divalproex Sodium Extended-release 250mg
Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
• DEPAKOTE 250mg
Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.

Locations

Country	Name	City	State
United States	Vince & Associates Clinical Research, Inc.	Overland Park	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
Vince & Associates Clinical Research, Inc.	Food and Drug Administration (FDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate generic divalproex sodium extended release to Depakote ER	This is an open-label, randomized, two-sequence, two-treatment, single dose, four-period, fully replicated crossover study in which 16 subjects will receive one of the two study drugs, Depakote ER or a generic equivalent, during each treatment period. Subjects will be patients with epilepsy who are otherwise healthy and who are stable on anti-epileptic therapy, not including any formulation of divalproex sodium.	Approximately 2.5 months	No